Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke Clinical Trial

Official title:

Short-term Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor in Chinese Population With Acute Ischemic Stroke: the Singe-center Real-world Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06134635
• Other study ID #: RMeng
• Status: Not yet recruiting
• Start date: December 1, 2023
• Est. completion date: December 1, 2024

Study information

• Verified date: October 2023
• Source: Xuanwu Hospital, Beijing
• Contact: Meng Ran, PhD
• Phone: +86-10-83199280
• Email: victor65[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective cohort study to investigate the early impact of evolocumab on patients with acute ischemic stroke (AIS) in China. Evolocumab, a proprotein convertase subtilisin/kexin taye 9 inhibitor, can significantly reduce low density lipoprotein cholesterol (LDL-C) levels and has a positive effect on improving cardiovascular events. However, existing studies have focused almost exclusively on the long-term effects of Evolocumab, and the early effects of Evolocumab on AIS patients remains unclear.

Description:

Patients aged 18-80 years old admitted to the Department of Neurology, Xuanwu Hospital, Capital Medical University, with a definite diagnosis of acute ischemic stroke and receiving lipid-lowering therapy with statins with or without evolocumab will be included in this study. Participants will be divided into two groups according to the lipid-lowering therapy they used: 1) statin-alone group: the participants receive statins alone (atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn) for lipid reduction, and 2) PCSK9-i group: the participants receive statins (atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn) and evolocumab (140mg twice a month) for lipid reduction. Most importantly, the lipid-lowering therapy of participants will be decided only by clinicians not involved in the study, not by the investigators. The levels of blood lipid (TC, TG, HDL-C, LDL-C, Apo AI and Apo B) and inflammatory biomarkers (hsCRP and IL-6) of these participants at different time points (day 1, day 3, day 5, and month 3) will be recorded. The target level of LDL-C is the LDL-C reduction ≥50% from the baseline and LDL-C<1.4mmol/L (55mg/dL). In addition, the cardiovascular events and adverse drug reactions of these participants during follow-up will also be recorded. During the follow-up period (3 months), participants who changed their lipid-lowering regimen, including the type, dosage and frequency of statins and evolocumab, will be excluded from the study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: December 1, 2024
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Diagnosed with acute ischemic stroke;

• Aged 18-80 years, gender unlimited;

• The fasting LDL-C=1.8mmol/L (70mg/dL);

• Received lipid-lowering therapy with statins with or without evolocumab;

• Premorbid mRS = 2;

• NIHSS = 15;

• Subjects participated in the study voluntarily and signed informed consent.

Exclusion Criteria:

• Participants who changed their lipid-lowering regimen;

• Participants allergic to PCSK9 inhibitors;

• Participants treated with cholesterol ester transfer protein inhibitor within 12 months prior to enrollment;

• LDL or plasma apheresis within 12 months prior to enrollment;

• Last known left ventricular ejection fraction < 30%

• Known hemorrhagic stroke at any time;

• Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2 at final screening;

• Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times;

• Pregnant or lactating women;

• Severe, concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 3 years.

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• Statins
Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
• Evolocumab
Evolocumab 140mg twice a month, subcutaneous injection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Xuanwu Hospital, Beijing

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LDL-C target achievement rate on Day 5, Month 3	LDL-C target achievement rate= Number of patients who achieved the LDL-C target level/ Total number of follow-up patients	Day 5, Month 3
Secondary	Percentage change in LDL-C level on Day 1, Day 3, Day 5, and Month 3	Percentage change in LDL-C level= (follow-up LDL-C level - baseline LDL-C level)/ baseline LDL-C level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage change in HDL-C level on Day 1, Day 3, Day 5, and Month 3	Percentage change in HDL-C level= (follow-up HDL-C level - baseline HDL-C level)/ baseline HDL-C level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage change in TC level on Day 1, Day 3, Day 5, and Month 3	Percentage change in TC level= (follow-up TC level - baseline TC level)/ baseline TC level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage change in TG level on Day 1, Day 3, Day 5, and Month 3	Percentage change in TG level= (follow-up TG level - baseline TG level)/ baseline TG level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage change in Apo AI level on Day 1, Day 3, Day 5, and Month 3	Percentage change in Apo AI level= (follow-up Apo AI level - baseline Apo AI level)/ baseline Apo AI level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage change in Apo B level on Day 1, Day 3, Day 5, and Month 3	Percentage change in Apo B level= (follow-up Apo B level - baseline Apo B level)/ baseline Apo B level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage change in hsCRP level on Day 1, Day 3, Day 5, and Month 3	Percentage change in hsCRP level= (follow-up hsCRP level - baseline hsCRP level)/ baseline hsCRP level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage change in IL-6 level on Day 1, Day 3, Day 5, and Month 3	Percentage change in IL-6 level= (follow-up IL-6 level - baseline IL-6 level)/ baseline IL-6 level	Day 1, Day 3, Day 5, Month 3
Secondary	Percentage of mRS=2 on Month 3	Percentage of mRS=2= Number of patients with mRS=2/ Total number of follow-up patients	Month 3
Secondary	Incidence of major cardiovascular events on Month 3	Major cardiovascular events: stroke, cardiovascular death, myocardial infarction, hospitalization for unstable angina, and coronary revascularization.	Month 3
Secondary	Incidence of adverse events on Month 3	Adverse events: injection site reaction, anaphylaxis, myopathy, abnormal liver function, new onset diabetes, cognitive impairment, and hemorrhagic cerebral infarction.	Month 3